Abstract
In vivo effects of a novel thromboxane A2/prostaglandin H2 (TXA2/PGH2) partial agonist, (+)5(Z)-7-[3-endo-phenylsulfonylamino[2.2.1]- bicyclohept-2-exo-yl]-heptenoic acid [(+)-S-145], on vascular, platelet and cardiac function.
G P Dubé, J A Jakubowski, K A Brune, K G Bemis and W L Kurtz
Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 799-807;